The tweet was deleted by the author.
But we saved everything 🙂.
OmniAb announced the introduction of OmniUltra, its dual modality in vivo discovery platform, during the TIDES USA event in Boston this week.
The OmniUltra platform is designed to enhance the discovery of novel human antibodies and peptides, aiming to accelerate innovation in therapeutic research. The event brings together industry leaders focused on advancing biologics and peptide therapeutics, and OmniAb is connecting with attendees to share information on its latest technology.
OmniAb previously presented the OmniUltra dual-modality in vivo discovery platform for antibodies and peptides at the 2026 PEGS Summit. The platform focuses on facilitating human antibody and peptide discovery. Its recent debut at TIDES USA continues the company's engagement with key industry events.